Table 2.
Treatment switching in patients aged >80 years and the total EXELS population
| Variable | Age categorya | |
|---|---|---|
| Age >80 years | Total | |
| Frequency of first switch b | ||
| Switch from any monotherapy | 91/395 (23.0) [18.9–27.2] | 902/3,596 (25.1) |
| Switch from HC monotherapy | 57/327 (17.4) [13.3–21.5] | 455/2,340 (19.4) |
| Switch from anagrelide monotherapy | 16/34 (47.1) [30.3–63.8] | 237/792 (30.0) |
| Reasons for first switch from HC | ||
| Intolerance/side effects | 18/57 (31.6) [19.5–43.6] | 127/455 (27.9) |
| Non-efficacious | 8/57 (14.0) [5.0–23.1] | 55/455 (12.1) |
| Subject preference | 1/57 (1.8) [0–5.2] | 9/455 (2.0) |
| Other | 17/57 (29.8) [17.9–41.7] | 133/455 (29.2) |
| Missing | 10/57 (17.5) [7.7–27.4] | 138/455 (30.3) |
| Unknown | 5/57 (8.8) [1.4–16.1] | 10/455 (2.2) |
| Reasons for first switch from anagrelide | ||
| Intolerance/side effects | 7/16 (43.8) [19.4–68.1] | 69/237 (29.1) |
| Non-efficacious | 0/16 (0.0) [NA] | 31/237 (13.1) |
| Subject preference | 1/16 (6.3) [0–18.1] | 13/237 (5.5) |
| Other (including economic) | 6/16 (37.5) [13.8–61.2] | 47/237 (19.8) |
| Missing | 2/16 (12.5) [0–28.7] | 76/237 (32.1) |
| Unknown | 0/16 (0.0) [NA] | 9/237 (3.8) |
CI confidence interval, HC hydroxycarbamide, NA not applicable
aValues are expressed as n (%) [95 % CI]
bPatients with missing data: n = 2